Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Ansbach – page 11

502 clinical trials in Ansbach, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Ansbach at a glance
502
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

502 trials in Ansbach

Open in trial search

Cardiomyopathy

Recruiting

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nucresiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Neuroblastoma+3

Recruiting

Long-term safety study of GD2IL18CART treatment in patients with neuroblastoma, osteosarcoma, Ewing sarcoma, or advanced breast cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:GD2IL18CART
  • Sponsor:Universitaet Muenster

Study of drug combination therapy for prevention of recurrent stroke in patients with acute ischemic stroke and atrial fibrillation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Flecainide Acetate
  • Sponsor:University Medical Center Hamburg-Eppendorf

Study of patritumab deruxtecan versus drug combination in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Study of Rilvegostomig with Bevacizumab and Tremelimumab as First-line Treatment for Patients with Advanced Liver Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:AstraZeneca AB

Evaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Ifinatamab Deruxtecan and Docetaxel for Patients with Advanced Prostate Cancer Resistant to Hormone Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Merck Sharp & Dohme LLC

Study on Pembrolizumab and Drug Combination for Patients with Recurrent Head and Neck Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Universitaet Des Saarlandes

Study Comparing Zilovertamab Vedotin with Drug Combination for Untreated Patients with Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Safety of CNTY-101 and Aldesleukin for Patients with Active Autoimmune Diseases: Lupus, Scleroderma, and Myositis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin
  • Sponsor:Universitaetsklinikum Erlangen AöR

Study on Ivosidenib for Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome with IDH1 Mutation After Stem Cell Transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ivosidenib
  • Sponsor:Technische Universitat Dresden

Study Comparing BMS-986393 CAR T Cell Therapy to Standard Treatments for Adults with Relapsed or Refractory Multiple Myeloma Resistant to Lenalidomide

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Celgene Corp.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Ansbach

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical research focusing on advanced breast cancer treatment, specifically targeting patients with estrogen receptor-positive and HER-2 negative variants of the disease.

  • Novel Therapeutic Combinations
  • Targeted Treatment Approaches
  • Hormone Receptor Studies

The research explores the effectiveness of combination therapies in treating metastatic breast cancer, particularly in cases with specific genetic mutations. These trials aim to advance treatment options and improve patient outcomes in advanced stages of the disease.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.